Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor, Neurology, Albert Einstein College of Medicine, discusses diagnostic components of idiopathic hypersomnia and emerging methods of treatment.
As a newly recognized disorder, idiopathic hypersomnia is characterized by excessive daytime sleepiness and potentially long nocturnal sleep time, with current methods of treatment leveraging therapies indicated for similar conditions such as narcolepsy, said Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor, Neurology, Albert Einstein College of Medicine.
Transcript
Can you discuss the heterogeneous nature of idiopathic hypersomnia? What are some current methods to evaluate its severity in patients?
Idiopathic hypersomnia is a relatively newly recognized disorder. Although some components of idiopathic hypersomnia have been known for many years, there’s been a little bit of confusion about the diagnostic criteria.
At one stage it was divided into 2 types: patients who had excessive daytime sleepiness with long sleep time, and patients who had excessive sleepiness that was independent of a long nocturnal sleep time. And more recently, the 2 types of idiopathic hypersomnia have sort of come down to one diagnostic category. There is a move to actually go back to the earlier diagnostic category of dividing into 2 separate types, but that’s in the proposal stage at this point.
So, idiopathic hypersomnia are basically people who have excessive daytime sleepiness, who don't meet the criteria for any other disorder of excessive sleepiness, such as narcolepsy or sleep deprivation or anything else.
So, in a way, it's sort of like an exclusion diagnosis. Patients who have idiopathic hypersomnia tend to have either a long nighttime sleep episode, in which case they may also have some sleepiness during the daytime.
Typically, under the new criteria, they need to sleep at least 11 hours at night in order to meet the criteria, but then there are other patients who don't have that long sleep episode and have a normal sleep duration at night, but are still sleepy during the daytime that don't have the typical features of narcolepsy—so can't be categorized as having narcolepsy.
There has never been a treatment for patients with idiopathic hypersomnia that's been FDA approved. And so most of the drugs that are used or medications that are used to treat narcolepsy have been applied to patients with idiopathic hypersomnia, but now, we have a first study of a drug for idiopathic hypersomnia that has entered into phase 3 studies that have now been completed. It shows an indication to be effective for the treatment of excessive sleepiness and patients with idiopathic hypersomnia.
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More